直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

In Sig Sauer, Patent Owner Weaponizes Non-Infringement Declaratory Judgement Claims to Deny Institution

July 10, 2025

Authored and Edited by Forrest A. Jones; Abigail N. Collins

In Sig Sauer Inc. v. Lone Star Future Weapons Inc., IPR2025-00410, Paper 13 (PTAB June 26, 2025), Acting Director Coke Morgan Stewart (Acting Director) exercised discretion to deny institution of the inter partes review (IPR) based primarily on a parallel declaratory judgment of a non-infringement counterclaim in a trade secret case. This was despite the fact that the validity of the patent was not at issue in the parallel litigation. The decision was further supported by the patent owner’s “settled expectations,” given the age of the patent.

Although the challenged patent was not part of the original trade secret suit, the Acting Director found the existence of “related litigation” persuasive in declining review. Most Fintiv discretionary factors focus on overlapping issues in parallel proceedings to avoid conflicting outcomes and inefficiency. In this case, there was no clear overlap between issues in the petition and those in the district court case. Trade secret disputes fall outside the PTAB’s scope, and the only patent issue raised was noninfringement—not invalidity. The issue of noninfringement is unrelated to validity challenges addressed in IPRs. Using such litigation as a basis for discretionary denial underscores the expansive reach of the Acting Director’s new discretionary denial process.

The Acting Director also found that the timing of the petition, combined with the patent’s age and the petitioner’s prior decision not to challenge it while developing a competing product, weighed against institution. In this case, the patent had been in force for ten years, creating “settled expectations.”

This decision reinforces for both petitioners and patent owners that the Acting Director is willing to entertain new reasons to either refer or deny. Even litigation unrelated to patent validity, such as trade secret disputes, may be used to justify denial. Both petitioners and patent owners should think creatively about arguments to present to the Board and not feel constrained to the normal Fintiv fact pattern.

Tags

patent owner, parallel litigation, Fintiv, discretionary denials

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Prosecution and Portfolio Management

Trade Secrets

Related Offices

Washington, DC

Contacts

Forrest A. Jones
Partner
Washington, DC
+1 202 408 4019
Email

*Abigail N. Collins is a Summer Associate at Finnegan.

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Lecture

IPIC/McGill Summer IP Course 2026: Understanding Trademarks

July 14, 2026

Montreal

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP